The present research was a double-blinded, randomized clinical trial and its population consisted of all patients afflicted with proven heliobacterpylori who visited the digestive clinic of Bandar Abbas in 2016-17. The subjects were randomly divided into two groups of 70. The control group underwent a triple therapy of pantoprazole 20mg, clarithromycin 500 mg and amoxicillin 1000 mg all taken twice a day plus a placebo for 14 days. The case group not only received the triple therapy but also Yomogi capsules (of dried S.boulardii 250 mg) twice a day. After 4 weeks of treatment, patients’ clinical symptoms were examined and UBT was used to assess the elimination of the disease.

The proportion of male to female subjects in the control and case groups was respectively 39 to 31 and 41 to 29 (p-value=.733). The mean age of the subjects in the control and case groups was respectively 35.21±9.69 and 33.79±10.32 years (p=.400). The elimination rate assessed by UBT in the control group was 70% and in the case group was 77.1% (p=.338).

The proportion of male to female subjects in the control and case groups was respectively 39 to 31 and 41 to 29 (p-value=.733). The mean age of the subjects in the control and case groups was respectively 35.21±9.69 and 33.79±10.32 years (p=.400). The elimination rate assessed by UBT in the control group was 70% and in the case group was 77.1% (p=.338).

The use of S.boulardii in the standard triple therapy not only managed to better control the patient’s clinical symptoms but also raised the elimination rate for about 7%.